Ying-Zhi Xu
Post Doctoral Fellow
Also affiliated: University of Nebraska–Lincoln (2012–2017); Colegio de Postgraduados (2012); Metabolon (United States) (2012)
Postdoc Researcher
Biochemistry & Molecular Biology, College of Medicine
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Ying-Zhi Xu's research focuses on understanding the molecular mechanisms underlying lymphoma, particularly Diffuse Large B-cell Lymphoma (DLBCL). Xu has investigated novel therapeutic targets and pathways involved in lymphoma progression. Recent work has explored the role of NEK2 as a potential therapeutic target and regulator of oncogenic pathways in lymphoma, identified through the use of a bifunctional inhibitor. Additionally, Xu has studied the targeting of a specific G-quadruplex in the CARD11 oncogene promoter. Development of new DLBCL mouse models is also part of this research effort. Xu collaborates with researchers at the University of Arkansas for Medical Sciences, including Mason McCrury, Kennith Swafford, Vijay Patel, and Sydnye L. Shuttleworth, with whom they have co-authored numerous publications.
Metrics
- h-index: 5
- Publications: 64
- Citations: 212
Selected Publications
-
Development of New Diffuse Large B Cell Lymphoma Mouse Models (2024)
Grants & Funding
As listed on this researcher's institutional profile.
- Role of HELB in the Replication Stress Response Dr. Tacketts COBRA through ACRI NIH/Nat. Inst. of General Medical Sciences via Arkansas Children's Research Institute Co-Investigator
Collaboration Network
Top Collaborators
- Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Development of New Diffuse Large B Cell Lymphoma Mouse Models
- Development of Humanized Diffuse Large B-Cell Lymphoma Mouse Models
- Abstract 1655: Development of humanized diffuse large B-cell lymphoma mouse models
- Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Development of Humanized Diffuse Large B-Cell Lymphoma Mouse Models
- Abstract 1655: Development of humanized diffuse large B-cell lymphoma mouse models
- Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Targeting a Novel G-Quadruplex in the CARD11 Oncogene Promoter with Naptho(2,1-b)furan-1-ethanol,2-nitro- Requires the Nitro Group
- Development of Humanized Diffuse Large B-Cell Lymphoma Mouse Models
- Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Development of New Diffuse Large B Cell Lymphoma Mouse Models
- Abstract 1655: Development of humanized diffuse large B-cell lymphoma mouse models
- Development of New Diffuse Large B Cell Lymphoma Mouse Models
- Abstract 1655: Development of humanized diffuse large B-cell lymphoma mouse models
- Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Targeting a Novel G-Quadruplex in the CARD11 Oncogene Promoter with Naptho(2,1-b)furan-1-ethanol,2-nitro- Requires the Nitro Group
- Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Targeting a Novel G-Quadruplex in the CARD11 Oncogene Promoter with Naptho(2,1-b)furan-1-ethanol,2-nitro- Requires the Nitro Group
- Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Targeting a Novel G-Quadruplex in the CARD11 Oncogene Promoter with Naptho(2,1-b)furan-1-ethanol,2-nitro- Requires the Nitro Group
- Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Targeting a Novel G-Quadruplex in the CARD11 Oncogene Promoter with Naptho(2,1-b)furan-1-ethanol,2-nitro- Requires the Nitro Group
- Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Targeting a Novel G-Quadruplex in the CARD11 Oncogene Promoter with Naptho(2,1-b)furan-1-ethanol,2-nitro- Requires the Nitro Group
- Development of Humanized Diffuse Large B-Cell Lymphoma Mouse Models
- Targeting a Novel G-Quadruplex in the CARD11 Oncogene Promoter with Naptho(2,1-b)furan-1-ethanol,2-nitro- Requires the Nitro Group
- Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
Similar Researchers
Based on overlapping research topics